Indeed, the combination of the glutaminase 1 (GLS1) inhibitor with PD1 and PD-L1 antibodies enhanced anti-tumor effectiveness by overcoming a metabolic checkpoint blocking T cell activation in CRC [313]. Here, GLS is linked to colorectal carcinoma.